In the realm of clinical studies, the nuances and enormous datasets necessitate utmost precision, swift actions, and efficiency. Astellas, a renowned global pharmaceutical leader, has brilliantly addressed this with its avant-garde Clinical Trial Management System (CTMS) AI through the use of a Robotic Process Automation Bot (BOT). This article dives deep into this groundbreaking technology, exploring its functionalities and the transformative impact on the clinical trial domain.

Decoding the Astellas CTMS BOT

Detailed by Olga Chomicova, Digital Transformation Lead at Astellas, in a recent presentation at Momentum Events’s Clinical Technology and Integration & Optimization Conference, the Clinical Trial Management System BOT is a state-of-the-art software robot tailored to automate tasks vital to the Clinical Trial Management System. Its backbone comprises advanced algorithms coupled with Automation Anywhere capabilities. The distinguishing feature, however, is its adeptness in seamlessly fetching, processing, and handling clinical trial data on a daily basis working as a “Digital Worker” supporting the human workforce.

Tracing the Origins of the CTMS BOT

Astellas pioneered the CTMS BOT to serve the diverse needs of clinical trials. Olga vividly described the day-to-day hurdles faced by professionals, like manually entering patient enrollment figures, diligently monitoring site visits, and perpetually updating clinical trial dates. Such manual methods were not just time-consuming but also error-prone, posing risks to the seamless flow of clinical operations and communications.

The Dynamics of the CTMS BOT in Clinical Trial Data Management

The CTMS BOT stands as a testament to innovation in clinical trial data management. Olga emphasized its design, specifically aimed at automating data entry tasks linked with the Clinical Trial Management System. Although she didn’t delve into the exact data sources during her talk, it’s conceivable that the Clinical Trial Management System BOT use could also be expanded to other eClinical tools, notably Electronic Data Capture (EDC) platforms and Astellas is leading the way through developing SAE Reconciliation Bot that works with Safety Database and EDC as well as external data managers which has helped reduce clinical trial costs. Such integration facilitates the bot in efficiently obtaining necessary data, processing it, and inputting it into the CTMS, making clinical trial monitoring and management more streamlined and error-free. The bot’s inherent machine-learning prowess ensures it evolves, tailoring itself to diverse data configurations.

Charting the Future Course

The horizon of clinical trials gleams with promise. As bots like the CTMS BOT progress, they may soon forecast clinical results, provide instantaneous feedback analysis, or even aid in crafting research conjectures from extensive datasets.

In Summary

Astellas’ CTMS BOT epitomizes the zenith of merging technology with clinical research. It symbolizes the forthcoming era of clinical trials where manual tasks transition to automation, ensuring data accuracy, promptness, and most importantly, safeguarding the sanctity of invaluable research.

Click here for more information on Momentum’s upcoming 2nd GCP Inspection Readiness Hybrid Event on December 4-6 in Philadelphia, PA. 

author avatar
Moe Alsumidaie Chief Editor
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.